개인구독
소속 기관이 없으신 경우, 개인 정기구독을 하시면 저렴하게
논문을 무제한 열람 이용할 수 있어요.
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2020.1
- 수록면
- 640 - 657 (18page)
이용수
초록· 키워드
오류제보하기
The worldwide prevalence of non-alcoholic fatty liver disease is around 25%, and that of nonalcoholic steatohepatitis (NASH) ranges from 1.5% to 6.45%. Patients with NASH, especially those with fibrosis, are at higher risk for adverse outcomes such as cirrhosis and liver-related mortality. Although vitamin E, pioglitazone, and liraglutide improved liver histology in randomized trials, there are currently no Food and Drug Administration-approved drugs for NASH. Five pharmacologic agents—obeticholic acid, elafibranor, cenicriviroc, resmetirom, and aramchol—are being evaluated in large, histology-based phase 3 trials. Within 2 to 4 years, new and effective drugs for the treatment of NASH are expected. Additionally, many phase 2 trials are ongoing for various agents. Based on the results of phase 2 and 3 trials, combination treatments are also being investigated. Future treatment strategies will comprise drug combinations and precision medicine based on the different phenotypes of NASH and treatment response of the individual patient.
목차
등록된 정보가 없습니다.
참고문헌 (100)
참고문헌 신청
Younossi ZM / 2016 / Global epidemiology of nonalcoholic fatty liver disease : meta-analytic assessment of prevalence, incidence, and outcomes / Hepatology 64:73~84
Angulo P / 2015 / Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease / Gastroenterology 149:389~397
Musso G / 2011 / Meta-analysis : natural history of non-alcoholic fatty liver disease(NAFLD)and diagnostic accuracy of non-invasive tests for liver disease severity / Ann Med 43:617~649
Vernon G / 2011 / Systematic review : the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults / Aliment Pharmacol Ther 34:274~285
Rafiq N / 2009 / Long-term follow-up of patients with nonalcoholic fatty liver / Clin Gastroenterol Hepatol 7:234~238
Angulo P / 2015 / Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease / Gastroenterology 149:389~397
Musso G / 2011 / Meta-analysis : natural history of non-alcoholic fatty liver disease(NAFLD)and diagnostic accuracy of non-invasive tests for liver disease severity / Ann Med 43:617~649
Vernon G / 2011 / Systematic review : the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults / Aliment Pharmacol Ther 34:274~285
Rafiq N / 2009 / Long-term follow-up of patients with nonalcoholic fatty liver / Clin Gastroenterol Hepatol 7:234~238
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials
Clinical and Molecular Hepatology
2023 .02
-
State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
Endocrinology and Metabolism
2022 .02
-
비알코올성 지방간 질환의 진단적 평가
대한내과학회지
2020 .10
-
Recent research trends and updates on nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2019 .01
-
Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology
Journal of Yeungnam Medical Science
2019 .01
-
Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology
영남의대학술지
2019 .01
-
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2020 .01
-
Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
Clinical and Molecular Hepatology
2023 .02
-
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management
Clinical and Molecular Hepatology
2023 .02
-
Recent advances in nonalcoholic fatty liver disease metabolomics
Clinical and Molecular Hepatology
2021 .10
-
Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed
Clinical and Molecular Hepatology
2023 .04
-
Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective
Clinical and Molecular Hepatology
2021 .01
-
A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease
Diabetes and Metabolism Journal
2024 .07
-
Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis
Clinical and Molecular Hepatology
2021 .01
-
The Immune Landscape in Nonalcoholic Steatohepatitis
Immune Network
2016 .06
-
Recent updates on pharmacologic therapy in nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2024 .01
-
Review of COVID-19 Therapeutics by Mechanism: From Discovery to Approval
Journal of Korean Medical Science
2024 .04
-
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Clinical and Molecular Hepatology
2023 .01
-
Beyond Liver Disease: Non-Alcoholic Fatty Liver Disease and Advanced Liver Fibrosis in Kidney Disease
Diabetes and Metabolism Journal
2022 .07
-
Global incidence of adverse clinical events in nonalcoholic fatty liver disease: A systematic review and meta-analysis
Clinical and Molecular Hepatology
2024 .04
이 논문의 저자 정보
최근 본 자료
댓글(0)
0